Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 19

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 19
---
 cellular metal imbalances. Preliminary studies suggest that Telomir-1 may achieve these outcomes by selectively binding to and exchanging between metal ions in a form- and dose-dependent manner, slowing enzyme reactivity, and preserving cellular functions. If clinical trials demonstrate its efficacy and it gains FDA and other regulatory approvals, we believe Telomir-1 could serve as a non-toxic, orally administered ion-overload regulator with the potential to balance enzyme and pathway overactivity caused by excessive metal reactivity.

TELI Pharmaceuticals, Inc.

3014 West Palmira Ave., Suite 302

Tampa, FL 33629

TELI Pharmaceuticals, Inc. (“TELI”) is a preclinical-stage pharmaceutical development company that licenses the international marketing rights to Telomir-1. More specifically, TELI is the exclusive licensee, through a license granted by MIRALOGX LLC, a Florida limited liability company, to use and sell Telomir-1 in the United Arab Amirates, Australia, Canada, China, European Union, Israel, India, Japan, South Korea, Mexico, Argentina, Taiwan and Uruguay, The full text of the Telomir-1 Licensing Agreement is attached as Annex E to this proxy statement.

| 8 |

The Merger (see page 28)

The Agreement and Plan of Merger, dated November 20, 2025 (“Merger Agreement”), was entered into by and among TELO Pharmaceuticals, Inc., a Florida corporation, TELOPHARM Acquisition Inc., a Delaware corporation and a wholly-owned subsidiary of TELO (“Merger Sub”), and TELI. Merger Sub will merge with and into TELI, with TELI being the surviving corporation (the “Merger”).

Pursuant to the Merger Agreement, at the Effective Time, each outstanding share of TELI Common Stock, will be converted into the right to receive such number of shares of common stock of TELO Common Stock, as is calculated in accordance with the Exchange Ratio, but in no instance will the amount of TELO Common Stock issued be greater than the number of outstanding TELO Common Stock as-of the closing date of the Merger. The Exchange Ratio is calculated using the relative company valuations of each of TELO and TELI, as determined by Moore (as further described herein). It is expected that shareholders of TELO will receive one share of TELI Common Stock for each share of TELI Common Stock held (the “Merger Share Consideration”). The